III期试验:盆腔放疗对比阴道近距离放疗联合紫杉醇/卡铂辅助治疗高危-中危及高危早期子宫内膜癌
这项随机III期试验纳入601例高危-中危或高危早期子宫内膜癌患者,比较盆腔放疗与阴道袖套近距离放疗联合紫杉醇/卡铂化疗的复发无生存(RFS)。中位随访53个月,两组60个月RFS均为0.76(HR 0.92;90%置信限0.69-1.23),未证明化疗联合阴道近距离放疗优于盆腔放疗;阴道近距离放疗联合化疗急性毒性更大,晚期毒性相似。
要点
- 阴道近距离放疗联合化疗与盆腔放疗的60个月RFS均为0.76,HR 0.92,未达优效。
- 阴道近距离放疗联合化疗组盆腔或腹主动脉旁淋巴结复发更常见(9% vs 4%)。
- 盆腔放疗仍是所有组织学类型高危早期子宫内膜癌有效且耐受良好的辅助治疗。
核心结论
- 未证明阴道近距离放疗联合紫杉醇/卡铂化疗优于盆腔放疗。
- 阴道近距离放疗联合化疗急性毒性更大,晚期毒性相似。
- 盆腔放疗仍是所有组织学类型高危早期子宫内膜癌有效、耐受良好且合适的辅助治疗。
研究设计与样本
- 随机III期试验,纳入601例符合条件的子宫内膜癌患者。
- 纳入标准为国际妇产科联盟(2009)I期子宫内膜样组织学且符合妇科肿瘤组方案33高危-中危标准、II期疾病、或I-II期浆液性或透明细胞肿瘤。
- 随机分配至盆腔放疗(45-50.4 Gy,5周)或阴道袖套近距离放疗后静脉紫杉醇175 mg/m2(3小时)联合卡铂(曲线下面积6),每21天一次,共3个周期。
主要发现
- 患者中位年龄63岁,74%为I期疾病。
- 组织学包括子宫内膜样71%、浆液性15%、透明细胞5%。
- 中位随访53个月,60个月RFS盆腔放疗组为0.76(95% CI 0.70-0.81),阴道近距离放疗联合化疗组为0.76(95% CI 0.70-0.81),HR 0.92(90%置信限0.69-1.23)。
- 60个月总生存盆腔放疗组为0.87(95% CI 0.83-0.91),阴道近距离放疗联合化疗组为0.85(95% CI 0.81-0.90),HR 1.04(90%置信限0.71-1.52)。
- 阴道和远处复发率两组相似;盆腔或腹主动脉旁淋巴结复发在阴道近距离放疗联合化疗组更常见(9% vs 4%)。
关键数值与推荐
- 60个月RFS:盆腔放疗组0.76(95% CI 0.70-0.81)vs 阴道近距离放疗联合化疗组0.76(95% CI 0.70-0.81)。
- 60个月总生存:盆腔放疗组0.87(95% CI 0.83-0.91)vs 阴道近距离放疗联合化疗组0.85(95% CI 0.81-0.90)。
- 盆腔或腹主动脉旁淋巴结复发:阴道近距离放疗联合化疗组9% vs 盆腔放疗组4%。
临床怎么用
- 盆腔放疗仍是所有组织学类型高危早期子宫内膜癌有效、耐受良好且合适的辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma. PATIENTS AND METHODS: A randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group protocol 33-based high-intermediate-risk criteria, stage II disease, or stage I to II serous or clear cell tumors. Treatment was randomly assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m2 (3 hours) plus carboplatin (area under the curve, 6) every 21 days for three cycles. RESULTS: The median age of the 601 patients was 63 years, and 74% had stage I disease. Histologies included endometrioid (71%), serous (15%), and clear cell (5%). With a median follow-up of 53 months, the 60-month RFS was 0.76 (95% CI, 0.70 to 0.81) for RT and 0.76 (95% CI, 0.70 to 0.81) for VCB/C (hazard ratio, 0.92; 90% confidence limit, 0.69 to 1.23). The 60-month overall survival was 0.87 (95% CI, 0.83 to 0.91) for RT and 0.85 (95% CI, 0.81 to 0.90) for VCB/C (hazard ratio, 1.04; 90% confidence limit, 0.71 to 1.52). Vaginal and distant recurrence rates were similar between arms. Pelvic or para-aortic nodal recurrences were more common with VCB/C (9% v 4%). There was no heterogeneity of treatment effect with respect to RFS or overall survival among clinical or pathologic variables evaluated. CONCLUSION: Superiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.
引用
- Randall ME, Filiaci V, McMeekin DS, et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019. PMID: 30995174. doi:10.1200/JCO.18.01575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。